Share on LinkedInShare on LinkedIn

ARTICLE · 07 APRIL 2009

FTC "No Action" On Pharmaceutical Patent Settlements Does Not Spell End To Reverse Payments Dispute

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

Earlier this month, Federal Trade Commission staff sent letters to four pharmaceutical companies disclosing its current intention not to challenge pharmaceutical litigation settlement agreements.

United StatesAntitrust/Competition Law

Earlier this month, Federal Trade Commission staff sent letters to four pharmaceutical companies disclosing its current intention not to challenge pharmaceutical litigation settlement agreements. Despite press reports that these letters reflect a decision by the FTC not to challenge a "reverse payment" settlement, the pharmaceutical industry should not assume that the FTC is relenting in its pursuit of patent infringement settlements that it believes are anticompetitive.

The U.S. "Hatch-Waxman" law allows the manufacturer of the generic bioequivalent of a drug that already has been approved to rely on the Food and Drug Administration's prior determination of the safety and efficacy of the branded drug. The generic manufacturer may file an "abbreviated" new drug application and, if it seeks approval to market its generic drug before the expiration of the patent covering the existing drug, give notice that it believes the patent to be invalid or not infringed. The

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from